US Transcatheter Aortic Valve Replacement Market Industry Trends and Forecast to 2034: Segmented by (Valve, Approach, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$3.11 BnPlaceholder estimate
Estimate 2025$3.33 Bn43.1% of the global market
Projected 2034$6.23 Bn 87%Adds $2.90 Bn over 9 forecast years
CAGR 2025–20347.2%Faster than 53% of 173 Medical Devices markets here
Key players5
US is 43.13% of the global market.
In North America, the largest is US (this report) at $3.33 Bn.
33 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Transcatheter Aortic Valve Replacement Market Analysis Executive Summary
Transcatheter aortic valve replacement replaces a narrowed heart valve through a catheter instead of open-heart surgery.
Key segments of the transcatheter Aortic Valve Replacement market include valve (Balloon-Expandable, Self-Expanding and Mechanically Expanded) and approach (Transfemoral, Transapical and Other Access).
US Transcatheter Aortic Valve Replacement market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Transcatheter Aortic Valve Replacement Market Dynamics
Market Growth Drivers
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the transcatheter Aortic Valve Replacement market.
Opportunity
Less invasive procedures, remote monitoring of implanted devices and rising access to cardiac care in emerging markets give the transcatheter Aortic Valve Replacement market room to grow.
Market Restraints
High device prices, the need for trained specialists, reimbursement pressure and product recalls hold back the transcatheter Aortic Valve Replacement market.
Competitive Landscape for Transcatheter Aortic Valve Replacement Market in US
The transcatheter Aortic Valve Replacement market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Transcatheter Aortic Valve Replacement Market in US
Transcatheter Aortic Valve Replacement in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 33 studies on Transcatheter Aortic Valve Replacement that are recruiting, active or about to start in the US.[3] Early deaths from long-term diseases: 12.6% in 2023, the latest WHO figure for the US.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how transcatheter Aortic Valve Replacement products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Valve
4.2 By Approach
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Edwards Lifesciences
7.2 Medtronic
7.3 Boston Scientific
7.4 Abbott Laboratories
7.5 Meril Life Sciences
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The transcatheter Aortic Valve Replacement market can be segmented based on various criteria, including valve, approach and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Transcatheter Aortic Valve Replacement right now, from free public sources.
How big is the Transcatheter Aortic Valve Replacement market in the US?
Placeholder estimate: about $3.33 Bn in 2025, rising to about $6.23 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Transcatheter Aortic Valve Replacement market in the US growing?
Placeholder estimate: about 7.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Transcatheter Aortic Valve Replacement market report cover?
The report splits the market by valve (Balloon-Expandable, Self-Expanding, Mechanically Expanded), approach (Transfemoral, Transapical, Other Access) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Transcatheter Aortic Valve Replacement market?
Key players include Edwards Lifesciences, Medtronic, Boston Scientific Corporation, Abbott Laboratories and Meril Life Sciences.
What is driving the Transcatheter Aortic Valve Replacement market?
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the transcatheter Aortic Valve Replacement market.
Who regulates Transcatheter Aortic Valve Replacement in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Transcatheter Aortic Valve Replacement are running in the US?
33 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Early deaths from long-term diseases: 12.6% in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Early deaths from long-term diseases (WHO) (%). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.